Addressing Cryptosporidium Infection among Young Children in Low-Income Settings: The Crucial Role of New and Existing Drugs for Reducing Morbidity and Mortality

PLoS Neglected Tropical Diseases

Volumn 10, Issue 1, 2016, Pages

  Shoultz, David A ^a   de Hostos, Eugenio L ^a   Choy, Robert K M ^a  

^a PATH ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AURANOFIN; AZITHROMYCIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE INHIBITOR; NEW DRUG; NITAZOXANIDE; OLEYLPHOSPHOCHOLINE; ORAL REHYDRATION SOLUTION; PITAVASTATIN; PYRVINIUM EMBONATE; STOMACH SECRETION INHIBITOR; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT;

AFRICA; ASIA; CENTRAL AFRICA; CHILDHOOD MORTALITY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; CRYPTOSPORIDIUM BOVIS; CRYPTOSPORIDIUM PARVUM; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DYSBIOSIS; EDITORIAL; ENTEROPATHY; HEALTH CARE COST; HUMAN; INFECTION SENSITIVITY; INTESTINE FLORA; KENYA; LOWEST INCOME GROUP; MALNUTRITION; MORBIDITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOGEN LOAD; PUBLIC HEALTH CAMPAIGN; SOUTH AMERICA; SOUTH AND CENTRAL AMERICA; STUNTING; UNITED NATIONS; DIARRHEA; DRUG EFFECTS; ECONOMICS; FEMALE; INFANT; MALE; MORTALITY; PHYSIOLOGY; POVERTY; PRESCHOOL CHILD;

AFRICA; ANTIPROTOZOAL AGENTS; CHILD, PRESCHOOL; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; DIARRHEA; FEMALE; HUMANS; INFANT; MALE; MORBIDITY; POVERTY;

EID: 84961346505     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004242     Document Type: Editorial

References (56)

1. UNICEFCommitting to Child Survival: A Promise Renewed—Progress Report 2013. New York: UNICEF; 2013. http://www.unicef.org/publications/index_70354.html.
2. Bhutta ZA, Black RE, Global Maternal, Newborn, and Child Health—So Near and Yet So Far. N Engl J Med. 2013;369: 2226–35. doi: http://www.nejm.org/doi/full/10.1056/NEJMra1111853 24304052
3. Keusch GT, Fontaine O, Bhargave A, Boschi-Pinto C, Bhutta ZA, Gotuzzo E, Jamison DT, Breman JG, Measham AR, et al. Diarrheal diseases. In: Disease Control Priorities in Developing Countries. 2nd ed. Washington, DC: World Bank; 2006: 371–87.
4. United NationsThe Millennium Development Goals Report. New York: United Nations; 2015. http://www.un.org/millenniumgoals/2015_MDG_Report/pdf/MDG%202015%20rev%20(July%201).pdf.
5. United NationsOpen Working Group Proposal for Sustainable Development Goals. New York: United Nations; 2013. http://undocs.org/A/68/970.
6. De Hostos EL, Choy RK, Nguyen T, Developing novel antisecretory drugs to treat infectious diarrhea. Future Med Chem. 2011;3(10): 1317–25. doi: 10.4155/fmc.11.87 21859305
7. World Health OrganizationUNICEFEnd Preventable Deaths: Global Action Plan for Prevention and Control of Pneumonia and Diarrhoea. Geneva: World Health Organization; 2013. http://www.unicef.org/media/files/Final_GAPPD_main_Report-_EN-8_April_2013.pdf.
8. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet. 2013;382(9888): 209–22. doi: 10.1016/S0140-6736(13)60844-2 23680352
9. Platts-Mills JA, Babji S, Bodhidatta L, Gratz J, Haque R, Havt A, et al. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). Lancet Glob Health. 2015;3(9): e564–75. doi: 10.1016/S2214–109X(15)00151–5 26202075
10. Agnew DG, Lima AA, Newman RD, Wuhib T, Moore RD, Guerrant RL, et al. Cryptosporidiosis in northeastern Brazilian children: association with increased diarrhea morbidity. J Infect Dis. 1998;177(3): 754–60. 9498458
11. Guerrant DI, Moore SR, Lima AA, Patrick PD, Schorling JB, Guerrant RL, Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four–seven years later in a poor urban community in northeast Brazil. Am J Trop Med Hyg. 1999;61: 707–13. 10586898
12. Alcantara CS, Yang CH, Steiner TS, Barrett LJ, Lima AA, Chappell CL, et al. Interleukin-8, tumor necrosis factor-α, and lactoferrin in immunocompetent hosts with experimental and Brazilian children with acquired cryptosporidiosis. Am J Trop Med Hyg. 2003;68(3): 325–28. 12685639
13. Lang D, MAL-ED Network InvestigatorsOpportunities to assess factors contributing to the development of the intestinal microbiota in infants living in developing countries. Microb Ecol Health Dis. 2015;26: 28316. doi: 10.3402/mehd.v26.28316 26031686
14. Ajjampur SS, Sarkar R, Sankaran P, Kannan A, Menon VK, Muliyil J, et al. Symptomatic and asymptomatic Cryptosporidium infections in children in a semi-urban slum community in southern India. Am J Trop Med Hyg. 2010;83(5): 1110–5. doi: 10.4269/ajtmh.2010.09–0644 21036847
15. Rheingans R, Kukla M, Adegbola RA, Debasish S, Omore R, Breiman RF, et al. Exploring household economic impacts of childhood diarrheal illnesses in 3 African settings. Clin Infect Dis. 2012;55(Suppl 4): S317–26. doi: 10.1093/cid/cis763 23169944
16. UNICEFAt a glance: Gambia. New York: UNICEF; updated 2013 December 26. http://www.unicef.org/infobycountry/gambia_statistics.html.
17. UNICEFKenya. New York: UNICEF; updated 2013 December 27. http://www.unicef.org/infobycountry/kenya_statistics.html.
18. UNICEFMali. New York: UNICEF; updated 2013 December 27. http://www.unicef.org/infobycountry/mali_statistics.html.
19. The World Bank GroupHealth expenditure per capita (current US$). Washington: The World Bank Group; updated 2014. http://data.worldbank.org/indicator/SH.XPD.PCAP.
20. Tyzzer EE, A sporozoon found in the peptic glands of the common mouse. Pro Soc Exp Biol Med. 1907;5: 12–13.
21. Nime FA, Burek JD, Page DL, Holscher MA, Yardley JH, Acute enterocolitis in a human being infected with the protozoan Cryptosporidium. Gastroenterology. 1976;70(4): 592–98. 815126
22. Bird RG, Smith MD, Cryptosporidiosis in man: parasite life cycle and fine structural pathology. J Pathol. 1980;132(3): 217–33. 7431158
23. Tzipori S, Smith M, Birch C, Barnes G, Bishop R, Cryptosporidiosis in hospital patients with gastroenteritis. Am J Trop Med Hyg. 1983;32(5): 931–34. 6625074
24. Tzipori S, Cryptosporidium: notes on epidemiology and pathogenesis. Parasitol Today. 1985;1(6): 159–65. 15275573
25. Current WL, Reese NC, Ernst JV, Bailey WS, Heyman MB, Weinstein WM, Human cryptosporidiosis in immunocompetent and immunodeficient persons. Studies of an outbreak and experimental transmission. N Engl J Med. 1983;308(21): 1252–7. 6843609
26. Holley HP, JrDover C, Cryptosporidium: a common cause of parasitic diarrhea in otherwise healthy individuals. J Infect Dis. 1986;153(2): 365–8. 3944486
27. Casemore DP, Sands RL, Curry A, Cryptosporidium species a “new” human pathogen. J Clin Pathol. 1985;38(12): 1321–36. 3908490
28. Bogaerts J, Lepage P, Rouvroy D, Vandepitte J, Cryptosporidium spp., a frequent cause of diarrhea in Central Africa. J Clin Microbiol. 1984;20(5): 874–6. 6210302
29. Checkley W, White AC, JrJagnath D, Arrowood MJ, Chalmers RM, Chen XM, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis. 2015;15(1): 85–94. doi: 10.1016/S1473-3099(14)70772-8 25278220
30. Ryan U, Hijjawi N, New developments in Cryptosporidium research. Int J Parasitol. 2015;45(6): 367–73. doi: 10.1016/j.ijpara.2015.01.009 25769247
31. Mead JR, Prospects for immunotherapy and vaccines against Cryptosporidium. Hum Vaccin Immunother. 2014;10(6): 1505–13. doi: 10.4161/hv.28485 24638018
32. Egger M, Mäusezahl D, Odermatt P, Symptoms and transmission of intestinal cryptosporidiosis. Arch Dis Child. 1990;65(4): 445–7. 2346340
33. Sarkar R, Ajjampur SS, Prabakaran AD, Geetha JC, Sowmyanarayanan TV, Kane A, et al. Cryptosporidiosis among children in an endemic semiurban community in southern India: does a protected drinking water source decrease infection? Clin Infect Dis. 2013;57: 398–406. doi: 10.1093/cid/cit288 23709650
34. Zwisler G, Simpson E, Moodley M, Treatment of diarrhea in young children: results from surveys on the perception and use of oral rehydration solutions, antibiotics, and other therapies in India and Kenya. J Glob Health. 2013;3(1): 010403. doi: 10.7189/jogh.03.010403 23826507
35. Centers for Disease Control and PreventionParasites—Cryptosporidium. Treatment—Nitazoxanide. Atlanta: Centers for Disease Control and Prevention; updated 2010 November 2. http://www.cdc.gov/parasites/crypto/health_professionals/tx.html.
36. Rossignol JF, El-Gohary YM, Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment Pharmacol Ther. 2006;24(10): 1423–30. 17081163
37. Rossignol JF, Abu-Zekry M, Hussein A, Santoro G, Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet. 2006;368(9350): 124–9.
38. Rossignol JF, Lopez-Chegne N, Julcamoro LM, Carrion ME, Bardin MC, Nitazoxanide for the empiric treatment of pediatric infectious diarrhea. Trans R Soc Trop Med Hyg. 2012;106(3): 167–73. doi: 10.1016/j.trstmh.2011.11.007 22301075
39. Hotez PJ, Could nitazoxanide be added to other essential medicines for integrated neglected tropical disease control and elimination? PLoS Negl Trop Dis. 2014;8(3): e2758. doi: 10.1371/journal.pntd.0002758 24675990
40. Amadi B, Mwiya M, Musuku J, Watuka A, Sianongo S, Ayoub A, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet. 2002;360(9343): 1375–80. 12423984
41. Abubakar I, Aliyu SH, Arumugam C, Usman NK, Hunter PR, Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis. Br J Clin Pharmacol. 2007;63(4): 387–93. doi: 10.1111/j.1365-2125.2007.02873.x 17335543
42. Policy CuresG-FINDER 2014 Neglected Disease Research and Development: Emerging Trends. Sydney: Policy Cures; 2014. http://www.policycures.org/downloads/Y7%20GFINDER%20full%20report%20web%20.pdf.
43. Light DW, Andrus JK, Warburton RN, Estimated research and development costs of rotavirus vaccines. Vaccine. 2009;27(47): 6627–33. doi: 10.1016/j.vaccine.2009.07.077 19665605
44. Rossignol JF, Ayoub A, Ayers MS, Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis. 2001;184(1): 103–6. 11398117
45. Rossignol JF, Kabil SM, El-Gohary Y, Younis AM, Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species. Clin Gastroenterol Hepatol. 2006;4(3): 320–24. 16527695
46. Amadi B, Mwiya M, Sianongo S, Payne L, Watuka A, Katubulushi M, et al. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC Infect Dis. 2009;9: 195. doi: 10.1186/1471–2334–9–195 19954529
47. Legrand F, Grenouillet F, Larosa F, Dalle F, Saas P, Millon L, et al. Diagnosis and treatment of digestive cryptosporidiosis in allogeneic haematopoietic stem cell transplant recipients: a prospective single centre study. Bone Marrow Transplant. 2011;46(6): 858–62. doi: 10.1038/bmt.2010.200 20729925
48. Hong DK, Wong CJ, Gutierrez K, Severe cryptosporidiosis in a seven-year-old renal transplant recipient: case report and review of the literature. Pediatr Transplant. 2007;11(1): 94–100. 17239130
49. Downey AS, Chong CR, Graczyk TK, Sullivan DJ, Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model. Antimicrob Agents Chemother. 2008;52(9): 3106–12. doi: 10.1128/AAC.00207–08 18591280
50. Bessoff K, Sateriale A, Lee KK, et al. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth. Antimicrob Agents Chemother. 2013;57(4): 1808–14.
51. Debnath A, Ndao M, Reed SL, Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases. Gut Microbes. 2013;4(1): 66–71. doi: 10.4161/gmic.22596 23137963
52. Castellanos-Gonzalez A, White AC, JrOjo KK, Vidadala RS, Zhang Z, Reid MC, et al. A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. J Infect Dis. 2013;208(8): 1342–8. doi: 10.1093/infdis/jit327 23878324
53. Gorla SK, McNair NN, Yang G, Gao S, Hu M, Jala VR, et al. Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis. Antimicrob Agents Chemother. 2014;58(3): 1603–14. doi: 10.1128/AAC.02075–13 24366728
54. Guo F, Zhang H, Fritzler JM, et al. Amelioration of Cryptosporidium parvum infection in vitro and in vivo by targeting parasite fatty acyl-coenzyme A synthetasis. J Infect Dis. 2014:209(8): 1279–87. doi: 10.1093/infdis/jit645 24273180
55. Sonzogni-Desautels K, Renteria A, Camargo F, et al. Oleylphosphocholine (OIPC) arrests Cryptosporidium parvum growth in vitro and prevents lethal infection in interferon gamma receptor knock-out mice. Front Microbiol. 2015;6: 973. doi: 10.3389/fmicb.2015.00973 26441906
56. Bessoff K, Spangenberg T, Foderaro JE, Jumani RS, Ward GE, Huston CD, Identification of Cryptosporidium parvum active chemical series by Repurposing the open access malaria box. Antimicrob Agents Chemother. 2014;58(5): 2731–9. doi: 10.1128/AAC.02641–13 24566188